» Articles » PMID: 33287201

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Dec 8
PMID 33287201
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes mellitus (T2DM) increases morbimortality in humans via enhanced susceptibility to cardiovascular disease (CVD). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are drugs designed for T2DM treatment to diminish hyperglycaemia by reducing up to 90% of renal tube glucose reabsorption. Clinical studies also suggest a beneficial action of SGLT2i in heart failure and CVD independent of its hypoglycaemiant effect. In the present study, we explored the effect of SGLT2i dapagliflozin (DAPA) in the metabolism and atherosclerosis in mice, which display accelerated atherosclerosis induced by insulin resistance. DAPA treatment of mice, which were fed a high-fat, high-cholesterol diet, failed to modify body weight, plasma glucose or lipid. Carbohydrate metabolism characterisation showed no effect of DAPA in the glucose tolerance test (GTT) despite augmented insulin levels during the test. In fact, decreased C-peptide levels in DAPA-treated mice during the GTT suggested impaired insulin release. Consistent with this, DAPA treatment of isolated islets displayed lower glucose-stimulated insulin secretion compared with vehicle-treated islets. Moreover, insulin-signalling experiments showed decreased pAKT activation in DAPA-treated adipose tissue indicating impaired insulin signalling in this tissue. No changes were seen in lesion size, vulnerability or content of macrophages, vascular smooth muscle cells, T cells or collagen. DAPA did not affect circulating inflammatory cells or cytokine levels. Hence, this study indicates that DAPA does not protect against atherosclerosis in insulin-resistant mice in hypercholesterolemic conditions.

Citing Articles

Atherosclerotic and Cardio-Metabolic Diseases: From Molecular Basis to Therapeutic Advances.

Kassi E, Kyrou I, Randeva H Int J Mol Sci. 2023; 24(11).

PMID: 37298686 PMC: 10253952. DOI: 10.3390/ijms24119737.


The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials.

Ji L, Mishra M, De Geest B Pharmaceutics. 2023; 15(4).

PMID: 37111578 PMC: 10140883. DOI: 10.3390/pharmaceutics15041092.


Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.

Liu Z, Ma X, Ilyas I, Zheng X, Luo S, Little P Theranostics. 2021; 11(9):4502-4515.

PMID: 33754074 PMC: 7977463. DOI: 10.7150/thno.54498.

References
1.
McMurray J, DeMets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A . A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21(5):665-675. PMC: 6607736. DOI: 10.1002/ejhf.1432. View

2.
Scheen A . Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018; 122(10):1439-1459. PMC: 5959222. DOI: 10.1161/CIRCRESAHA.117.311588. View

3.
Di Pino A, DeFronzo R . Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev. 2019; 40(6):1447-1467. PMC: 7445419. DOI: 10.1210/er.2018-00141. View

4.
Libby P, Buring J, Badimon L, Hansson G, Deanfield J, Bittencourt M . Atherosclerosis. Nat Rev Dis Primers. 2019; 5(1):56. DOI: 10.1038/s41572-019-0106-z. View

5.
Lovshin J, Cherney D . Sodium transport in diabetes: two sides to the coin. Nat Rev Nephrol. 2018; 15(3):125-126. DOI: 10.1038/s41581-018-0106-3. View